2023
DOI: 10.3390/toxins16010019
|View full text |Cite
|
Sign up to set email alerts
|

Improvement in Quality-of-Life-Related Outcomes Following Treatment with IncobotulinumtoxinA in Adults with Limb Spasticity: A Pooled Analysis

Franco Molteni,
Jörg Wissel,
Klemens Fheodoroff
et al.

Abstract: A strong correlation has been reported between patient-reported quality of life (QoL) and the investigator-rated Disability Assessment Scale (DAS) in patients with spasticity. The current analysis evaluates the effect of incobotulinumtoxinA on QoL-related outcomes (limb position abnormality, as well as dressing- and hygiene-related disability, measured with the DAS) in adults with upper limb spasticity, using pooled data from six studies. Separate analyses for each DAS domain were performed using data from pat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 76 publications
0
1
0
Order By: Relevance
“…Spasticity is a common complication in patients with severe stroke that leads to pain and significant motor dysfunction. Treatment often involves long-term management strategies, including the use of botulinum toxin type A (BoNT-A), which has been widely adopted for its efficacy in reducing muscle hypertonicity and associated discomfort [8][9][10][11][12][13]. However, botulinum therapy is repetitive and invasive, and when administered alone it may not improve upper limb function; it Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s).…”
Section: Introductionmentioning
confidence: 99%
“…Spasticity is a common complication in patients with severe stroke that leads to pain and significant motor dysfunction. Treatment often involves long-term management strategies, including the use of botulinum toxin type A (BoNT-A), which has been widely adopted for its efficacy in reducing muscle hypertonicity and associated discomfort [8][9][10][11][12][13]. However, botulinum therapy is repetitive and invasive, and when administered alone it may not improve upper limb function; it Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s).…”
Section: Introductionmentioning
confidence: 99%